Rosa Macancela
Nurse Practitioner · New York, NYNPI 1669845533
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 93.6% of the total across 179 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 20 manufacturers reported payments, led by AstraZeneca at 29.6% of the total. 2025 is the largest year on record at $3,730, 3.4 times the $1,091 reported in 2023. Among nurse practitioner clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 179 payments — averaging $44.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- Boehringer Ingelheim$976
- Alnylam Pharmaceuticals Inc.$633
- Cvrx, Inc.$507
- Novo Nordisk$490
- Bridgebio Pharma, Inc.$462
- plus $3K from 14 others
What the payments were for
- Travel & lodging$5076%
- Food & beverage$7,40294%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 46 | $2,338 |
| Boehringer Ingelheim | 15 | $976 |
| Alnylam Pharmaceuticals Inc. | 9 | $633 |
| Cvrx, Inc. | 2 | $507 |
| Novo Nordisk | 9 | $490 |
| Bridgebio Pharma, Inc. | 29 | $462 |
| Scpharmaceuticals Inc. | 10 | $372 |
| E.r. Squibb & Sons, L.L.C. | 4 | $365 |
| United Therapeutics Corporation | 3 | $353 |
| Novartis | 17 | $322 |
| Kiniksa Pharmaceuticals International, PLC | 4 | $196 |
| Lexicon Pharmaceuticals, Inc. | 4 | $195 |
| Merck | 7 | $190 |
| Pfizer | 9 | $161 |
| Boston Scientific | 1 | $80 |
| Philips North America LLC | 2 | $73 |
| Heartflow, Inc. | 3 | $65 |
| Lilly USA, LLC | 3 | $61 |
| Kestra Medical Technology Services, Inc. | 1 | $47 |
| Actelion Pharmaceuticals US, Inc. | 1 | $23 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,909 in reported general payments places this provider in the 95th percentile of 4,112 nurse practitioner providers in New York.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Repatha SureclickEvolocumab | 18 | $10,944 |
| Metoprolol Succinate | 28 | $367 |
| Ezetimibe | 20 | $146 |
| Atorvastatin Calcium | 11 | $93 |
| Spironolactone | 12 | $45 |
Paid to pharmacies, not to this prescriber.
Other nurse practitioner in New York
- Patricia McGoldrickNew York$202K
- Jodi LogerfoNew York$48K
- Aileen FerrickNew York$26K
- Tsz Isabel WongNew York$25K
- Chris BustamanteNew York$22K
- Mayra PozoNew York$14K
- Janet JohnsonNew York$12K
- Rachel RankinNew York$10K
- Richelle CassellNew York$10K
- Michelle DartSyracuse$95K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.